Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31652344,peak concentration (Cmax ),"Values of peak concentration (Cmax ), area under curve (AUC), half-life, elimination constant, volume of distribution and clearance showed statistically significant differences when comparing women (604.34 ng h/ml, 127.36 ng/ml, 4.4 h, 0.18 1/h, 50.56 L and 8.55 L/h, respectively) and men (276.1 ng h/ml, 70.9 ng/ml, 3.3 h, 0.26 1/h, 91.42 L and 24.34 L/h, respectively), receiving the same dose (5 mg), respectively.",Comparative bioavailability of two zolpidem hemitartrate formulations in healthy human Brazilian volunteers using high-performance liquid chromatography coupled to tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31652344/),[h·ng] / [ml],604.34,10933,DB00425,Zolpidem
,31652344,volume of distribution,"Values of peak concentration (Cmax ), area under curve (AUC), half-life, elimination constant, volume of distribution and clearance showed statistically significant differences when comparing women (604.34 ng h/ml, 127.36 ng/ml, 4.4 h, 0.18 1/h, 50.56 L and 8.55 L/h, respectively) and men (276.1 ng h/ml, 70.9 ng/ml, 3.3 h, 0.26 1/h, 91.42 L and 24.34 L/h, respectively), receiving the same dose (5 mg), respectively.",Comparative bioavailability of two zolpidem hemitartrate formulations in healthy human Brazilian volunteers using high-performance liquid chromatography coupled to tandem mass spectrometry. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31652344/),l,50.56,10934,DB00425,Zolpidem
,31652344,volume of distribution,"Values of peak concentration (Cmax ), area under curve (AUC), half-life, elimination constant, volume of distribution and clearance showed statistically significant differences when comparing women (604.34 ng h/ml, 127.36 ng/ml, 4.4 h, 0.18 1/h, 50.56 L and 8.55 L/h, respectively) and men (276.1 ng h/ml, 70.9 ng/ml, 3.3 h, 0.26 1/h, 91.42 L and 24.34 L/h, respectively), receiving the same dose (5 mg), respectively.",Comparative bioavailability of two zolpidem hemitartrate formulations in healthy human Brazilian volunteers using high-performance liquid chromatography coupled to tandem mass spectrometry. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31652344/),[l] / [h],8.55,10935,DB00425,Zolpidem
,31652344,clearance,"Values of peak concentration (Cmax ), area under curve (AUC), half-life, elimination constant, volume of distribution and clearance showed statistically significant differences when comparing women (604.34 ng h/ml, 127.36 ng/ml, 4.4 h, 0.18 1/h, 50.56 L and 8.55 L/h, respectively) and men (276.1 ng h/ml, 70.9 ng/ml, 3.3 h, 0.26 1/h, 91.42 L and 24.34 L/h, respectively), receiving the same dose (5 mg), respectively.",Comparative bioavailability of two zolpidem hemitartrate formulations in healthy human Brazilian volunteers using high-performance liquid chromatography coupled to tandem mass spectrometry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31652344/),[l] / [h],8.55,10936,DB00425,Zolpidem
,10365644,Recovery,"Recovery of buspirone and 1-PP averaged 98% and 89%, respectively, and the limit of quantification was 0.2 ng/mL for both compounds.",Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365644/),%,98,13512,DB00425,Zolpidem
,10365644,Recovery,"Recovery of buspirone and 1-PP averaged 98% and 89%, respectively, and the limit of quantification was 0.2 ng/mL for both compounds.",Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365644/),%,89,13513,DB00425,Zolpidem
,21985609,peak plasma concentrations (C(max)),"4. In the two periods of treatments, the mean peak plasma concentrations (C(max)) were 56.4 ± 25.6 ng/mL (zolpidem alone) and 67.3 ± 25.8 ng/mL (zolpidem after pretreatment with fluvoxamine).",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),[ng] / [ml],56.4,16874,DB00425,Zolpidem
,21985609,peak plasma concentrations (C(max)),"4. In the two periods of treatments, the mean peak plasma concentrations (C(max)) were 56.4 ± 25.6 ng/mL (zolpidem alone) and 67.3 ± 25.8 ng/mL (zolpidem after pretreatment with fluvoxamine).",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),[ng] / [ml],67.3,16875,DB00425,Zolpidem
,21985609,t(max),"The t(max), times taken to reach C(max), were 0.83 ± 0.44 and 1.26 ± 0.74 h, respectively, and the total areas under the curve (AUC(0-∞)) were 200.9 ± 116.8 and 512.0 ± 354.6 ng h/mL, respectively.",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),h,0.83,16876,DB00425,Zolpidem
,21985609,t(max),"The t(max), times taken to reach C(max), were 0.83 ± 0.44 and 1.26 ± 0.74 h, respectively, and the total areas under the curve (AUC(0-∞)) were 200.9 ± 116.8 and 512.0 ± 354.6 ng h/mL, respectively.",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),h,1.26,16877,DB00425,Zolpidem
,21985609,total areas under the curve (AUC(0-∞)),"The t(max), times taken to reach C(max), were 0.83 ± 0.44 and 1.26 ± 0.74 h, respectively, and the total areas under the curve (AUC(0-∞)) were 200.9 ± 116.8 and 512.0 ± 354.6 ng h/mL, respectively.",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),[h·ng] / [ml],200.9,16878,DB00425,Zolpidem
,21985609,total areas under the curve (AUC(0-∞)),"The t(max), times taken to reach C(max), were 0.83 ± 0.44 and 1.26 ± 0.74 h, respectively, and the total areas under the curve (AUC(0-∞)) were 200.9 ± 116.8 and 512.0 ± 354.6 ng h/mL, respectively.",Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),[h·ng] / [ml],512.0,16879,DB00425,Zolpidem
,21985609,half-life,The half-life of zolpidem was 2.24 ± 0.81 h when given alone and 4.99 ± 2.92 h after pretreatment with fluvoxamine.,Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),h,2.24,16880,DB00425,Zolpidem
,21985609,half-life,The half-life of zolpidem was 2.24 ± 0.81 h when given alone and 4.99 ± 2.92 h after pretreatment with fluvoxamine.,Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985609/),h,4.99,16881,DB00425,Zolpidem
,10383565,50% inhibitory concentration (IC50 ),"Ketoconazole had a 50% inhibitory concentration (IC50 ) of 0.61 microm vs formation of the M-3 metabolite of zolpidem in vitro; in a clinical study, ketoconazole coadministration reduced zolpidem oral clearance by approximately 40%, somewhat less than anticipated based on the IC50 value and total plasma ketoconazole levels, but much more than predicted based on unbound plasma ketoconazole levels.","Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383565/),μm,0.61,18082,DB00425,Zolpidem
,8275648,Bioavailability,Bioavailability is 67% after oral doses of 5-20 mg.,Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275648/),%,67,25177,DB00425,Zolpidem
,22689921,flow rate,"The mobile phase, which consisted of a mixture of methanol and 20 mM ammonium formate (pH 5.00 ± 0.05; 75:25 v/v), was injected at a flow rate of 0.40 mL/min.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),[ml] / [min],0.40,27139,DB00425,Zolpidem
,22689921,retention times,The retention times of zolpidem and IS were approximately 1.76 and 1.22.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,1.76,27140,DB00425,Zolpidem
,22689921,retention times,The retention times of zolpidem and IS were approximately 1.76 and 1.22.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,1.22,27141,DB00425,Zolpidem
,22689921,run time,The LC run time was 3 min.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),min,3,27142,DB00425,Zolpidem
>,22689921,signal-to-noise (S/N),The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,3,27143,DB00425,Zolpidem
,22689921,signal-to-noise (S/N),The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),[ng] / [ml],0.04,27144,DB00425,Zolpidem
>,22689921,S/N,The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,10,27145,DB00425,Zolpidem
,22689921,S/N,The lower detection limit [(signal-to-noise (S/N) > 3] was 0.04 ng/mL and the lower limit of quantification (S/N > 10) was 0.10 ng/mL.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),[ng] / [ml],0.10,27146,DB00425,Zolpidem
,22689921,Recovery,Recovery of zolpidem in human plasma was 87.00% and IS recovery was 81.60%.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),%,87.00,27147,DB00425,Zolpidem
,22689921,recovery,Recovery of zolpidem in human plasma was 87.00% and IS recovery was 81.60%.,A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),%,81.60,27148,DB00425,Zolpidem
,22689921,T(max),"The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),h,1.25,27149,DB00425,Zolpidem
,22689921,C(max),"The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),[ng] / [ml],127.80,27150,DB00425,Zolpidem
,22689921,AUC(0→t),"The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,665.37,27151,DB00425,Zolpidem
,22689921,AUC(0→∞),"The primary pharmacokinetic parameters were T(max) (h) = (1.25 ± 0.725), C(max) (ng/mL) (127.80 ± 34.081), AUC(0→t), = (665.37 ± 320.982) and AUC(0→∞), 686.03 ± 342.952, respectively.",A rapid and highly sensitive UPLC-MS-MS method for the quantification of zolpidem tartrate in human EDTA plasma and its application to pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22689921/),,686.03,27152,DB00425,Zolpidem
,10595727,detection limit,The detection limit was 3 ng/ml for zolpidem using an ultraviolet detector operated at 240 nm.,Determination of zolpidem in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595727/),[ng] / [ml],3,32100,DB00425,Zolpidem
greater,10595727,recovery,The recovery was greater than 87% with analysis performed in 12 min.,Determination of zolpidem in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10595727/),%,87,32101,DB00425,Zolpidem
,25185933,total amount of sleep,The median total amount of sleep was 361.0 (interquartile range [IQR]: 299.0-418.5) minutes; approximately 65% of the normal reference value for an 8-hour period.,Relationship between zolpidem concentrations and sleep parameters in pediatric burn patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25185933/),min,361.0,45682,DB00425,Zolpidem
,11095577,elimination half-life,The pharmacokinetics of Ro 41-3290 were dose proportional with an elimination half-life of approximately 8 h.,"Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095577/),h,8,46035,DB00425,Zolpidem
,11095577,t(max),The relatively slow absorption of Ro 41-3290 (t(max) approximately 2.5 h) and the concentration-effect time delay do not make it a good candidate to replace its parent compound Ro 41-3696 as an investigational hypnotic.,"Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095577/),h,2.5,46036,DB00425,Zolpidem
,21058968,AUC,"After repeated administration of SJW, the mean values of AUC and C(max) for zolpidem significantly decreased (380.3 ± 181.4 vs. 265.4 ± 134.2 ng h/mL, P = 0.001; 83.1 ± 30.1 vs. 55.1 ± 24.8 ng/mL, P = 0.000 respectively) and the mean value of CL/F for zolpidem significantly increased (38.4 ± 31.5 vs. 56.9 ± 57.2 mL/min, P = 0.040).",Drug interaction between St John's wort and zolpidem in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058968/),[h·ng] / [ml],380.3,60751,DB00425,Zolpidem
,21058968,AUC,"After repeated administration of SJW, the mean values of AUC and C(max) for zolpidem significantly decreased (380.3 ± 181.4 vs. 265.4 ± 134.2 ng h/mL, P = 0.001; 83.1 ± 30.1 vs. 55.1 ± 24.8 ng/mL, P = 0.000 respectively) and the mean value of CL/F for zolpidem significantly increased (38.4 ± 31.5 vs. 56.9 ± 57.2 mL/min, P = 0.040).",Drug interaction between St John's wort and zolpidem in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058968/),[h·ng] / [ml],265.4,60752,DB00425,Zolpidem
,21058968,AUC,"After repeated administration of SJW, the mean values of AUC and C(max) for zolpidem significantly decreased (380.3 ± 181.4 vs. 265.4 ± 134.2 ng h/mL, P = 0.001; 83.1 ± 30.1 vs. 55.1 ± 24.8 ng/mL, P = 0.000 respectively) and the mean value of CL/F for zolpidem significantly increased (38.4 ± 31.5 vs. 56.9 ± 57.2 mL/min, P = 0.040).",Drug interaction between St John's wort and zolpidem in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058968/),[ng] / [ml],83.1,60753,DB00425,Zolpidem
,21058968,C(max),"After repeated administration of SJW, the mean values of AUC and C(max) for zolpidem significantly decreased (380.3 ± 181.4 vs. 265.4 ± 134.2 ng h/mL, P = 0.001; 83.1 ± 30.1 vs. 55.1 ± 24.8 ng/mL, P = 0.000 respectively) and the mean value of CL/F for zolpidem significantly increased (38.4 ± 31.5 vs. 56.9 ± 57.2 mL/min, P = 0.040).",Drug interaction between St John's wort and zolpidem in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058968/),[ng] / [ml],83.1,60754,DB00425,Zolpidem
,21058968,C(max),"After repeated administration of SJW, the mean values of AUC and C(max) for zolpidem significantly decreased (380.3 ± 181.4 vs. 265.4 ± 134.2 ng h/mL, P = 0.001; 83.1 ± 30.1 vs. 55.1 ± 24.8 ng/mL, P = 0.000 respectively) and the mean value of CL/F for zolpidem significantly increased (38.4 ± 31.5 vs. 56.9 ± 57.2 mL/min, P = 0.040).",Drug interaction between St John's wort and zolpidem in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058968/),[ng] / [ml],55.1,60755,DB00425,Zolpidem
,21058968,CL/F,"After repeated administration of SJW, the mean values of AUC and C(max) for zolpidem significantly decreased (380.3 ± 181.4 vs. 265.4 ± 134.2 ng h/mL, P = 0.001; 83.1 ± 30.1 vs. 55.1 ± 24.8 ng/mL, P = 0.000 respectively) and the mean value of CL/F for zolpidem significantly increased (38.4 ± 31.5 vs. 56.9 ± 57.2 mL/min, P = 0.040).",Drug interaction between St John's wort and zolpidem in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058968/),[ml] / [min],38.4,60756,DB00425,Zolpidem
,21058968,CL/F,"After repeated administration of SJW, the mean values of AUC and C(max) for zolpidem significantly decreased (380.3 ± 181.4 vs. 265.4 ± 134.2 ng h/mL, P = 0.001; 83.1 ± 30.1 vs. 55.1 ± 24.8 ng/mL, P = 0.000 respectively) and the mean value of CL/F for zolpidem significantly increased (38.4 ± 31.5 vs. 56.9 ± 57.2 mL/min, P = 0.040).",Drug interaction between St John's wort and zolpidem in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058968/),[ml] / [min],56.9,60757,DB00425,Zolpidem
,25728370,flow rate,"Chromatographic separation of ZPD was performed on a reversed-phase Luna C18 column (50 mm × 2.0 mm i.d., 5 μm particles) with a mobile phase of 10mM ammonium formate buffer (pH 3.0)-methanol (15:85, v/v) at a flow rate of 250 μm/min.",Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728370/),[μm] / [min],250,66995,DB00425,Zolpidem
,25728370,total run-time,"The total run-time was 2.5 min and the retention times of ZPD and IS were 0.66 and 0.74 min, respectively.",Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728370/),min,2.5,66996,DB00425,Zolpidem
,25728370,retention times,"The total run-time was 2.5 min and the retention times of ZPD and IS were 0.66 and 0.74 min, respectively.",Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728370/),min,0.66,66997,DB00425,Zolpidem
,25728370,retention times,"The total run-time was 2.5 min and the retention times of ZPD and IS were 0.66 and 0.74 min, respectively.",Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728370/),min,0.74,66998,DB00425,Zolpidem
,25728370,mass-to-charge transition,"The mass-to-charge transition monitored for quantification of ZPD and IS was 308.2→235.2 and 344.0→271.0, respectively.",Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728370/),,308.2,66999,DB00425,Zolpidem
,25728370,mass-to-charge transition,"The mass-to-charge transition monitored for quantification of ZPD and IS was 308.2→235.2 and 344.0→271.0, respectively.",Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728370/),,235.2,67000,DB00425,Zolpidem
,25728370,mass-to-charge transition,"The mass-to-charge transition monitored for quantification of ZPD and IS was 308.2→235.2 and 344.0→271.0, respectively.",Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728370/),,344.0,67001,DB00425,Zolpidem
,25728370,mass-to-charge transition,"The mass-to-charge transition monitored for quantification of ZPD and IS was 308.2→235.2 and 344.0→271.0, respectively.",Determination of zolpidem in human plasma by liquid chromatography-tandem mass spectrometry for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25728370/),,271.0,67002,DB00425,Zolpidem
,27574509,C MAX,Sex differences in PK were evident: females had a higher C MAX (112.4 vs. 68.1 ug/L) and AUC (537.8 vs.,Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],112.4,70205,DB00425,Zolpidem
,27574509,C MAX,Sex differences in PK were evident: females had a higher C MAX (112.4 vs. 68.1 ug/L) and AUC (537.8 vs.,Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],68.1,70206,DB00425,Zolpidem
,27574509,AUC,Sex differences in PK were evident: females had a higher C MAX (112.4 vs. 68.1 ug/L) and AUC (537.8 vs.,Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),,537.8,70207,DB00425,Zolpidem
,27574509,T MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),h,0.25,70208,DB00425,Zolpidem
,27574509,T MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),h,1,70209,DB00425,Zolpidem
,27574509,C MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],109.1,70210,DB00425,Zolpidem
,27574509,C MAX,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[ug] / [l],68.1,70211,DB00425,Zolpidem
,27574509,AUC,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[h(∗)ug] / [l],339.7,70212,DB00425,Zolpidem
,27574509,AUC,"Castration induced an earlier T MAX (0.25 vs. 1 h), greater C MAX (109.1 vs. 68.1 ug/L), and a corresponding AUC increase (339.7 vs. 231.8 h(∗)ug/L).",Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27574509/),[h(∗)ug] / [l],231.8,70213,DB00425,Zolpidem
,9871431,apparent oral clearance,"Mean apparent oral clearance of zolpidem when given with placebo was 422 mL/min, and elimination half-life was 1.9 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],422,71084,DB00425,Zolpidem
,9871431,elimination half-life,"Mean apparent oral clearance of zolpidem when given with placebo was 422 mL/min, and elimination half-life was 1.9 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),h,1.9,71085,DB00425,Zolpidem
,9871431,Clearance,"Clearance was significantly reduced to 250 mL/min when zolpidem was given with ketoconazole, and half-life was prolonged to 2.4 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],250,71086,DB00425,Zolpidem
,9871431,half-life,"Clearance was significantly reduced to 250 mL/min when zolpidem was given with ketoconazole, and half-life was prolonged to 2.4 hours.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),h,2.4,71087,DB00425,Zolpidem
,9871431,clearance,"Coadministration of zolpidem with itraconazole or fluconazole also reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],320,71088,DB00425,Zolpidem
,9871431,clearance,"Coadministration of zolpidem with itraconazole or fluconazole also reduced clearance (320 and 338 mL/min), but differences compared to the zolpidem plus placebo treatment did not reach significance.","Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871431/),[ml] / [min],338,71089,DB00425,Zolpidem
,9834048,apparent elimination half-life [t1/2],"However, zaleplon had more rapid elimination (apparent elimination half-life [t1/2] of 1 hour) and higher apparent oral clearance (approximately 4300 mL/min) than zolpidem (t1/2, 2.0 to 2.2 hours; apparent oral clearance, 340 to 380 mL/min).","Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834048/),h,1,75502,DB00425,Zolpidem
,9834048,apparent oral clearance,"However, zaleplon had more rapid elimination (apparent elimination half-life [t1/2] of 1 hour) and higher apparent oral clearance (approximately 4300 mL/min) than zolpidem (t1/2, 2.0 to 2.2 hours; apparent oral clearance, 340 to 380 mL/min).","Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834048/),[ml] / [min],4300,75503,DB00425,Zolpidem
,9834048,t1/2,"However, zaleplon had more rapid elimination (apparent elimination half-life [t1/2] of 1 hour) and higher apparent oral clearance (approximately 4300 mL/min) than zolpidem (t1/2, 2.0 to 2.2 hours; apparent oral clearance, 340 to 380 mL/min).","Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834048/),h,2.0 to 2.2,75504,DB00425,Zolpidem
,9834048,apparent oral clearance,"However, zaleplon had more rapid elimination (apparent elimination half-life [t1/2] of 1 hour) and higher apparent oral clearance (approximately 4300 mL/min) than zolpidem (t1/2, 2.0 to 2.2 hours; apparent oral clearance, 340 to 380 mL/min).","Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834048/),[ml] / [min],340 to 380,75505,DB00425,Zolpidem
,23609389,time to the maximum concentration,"The pharmacokinetic profile of almorexant was characterized by a median time to the maximum concentration of 1.5 hours, quick disposition with a distribution half-life of 1.6 hours, and rapidly decreasing concentrations to approximately 20% of the maximum concentration over 8 hours, with a terminal half-life of 32 hours.","Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609389/),h,1.5,82082,DB00425,Zolpidem
,23609389,distribution half-life,"The pharmacokinetic profile of almorexant was characterized by a median time to the maximum concentration of 1.5 hours, quick disposition with a distribution half-life of 1.6 hours, and rapidly decreasing concentrations to approximately 20% of the maximum concentration over 8 hours, with a terminal half-life of 32 hours.","Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609389/),h,1.6,82083,DB00425,Zolpidem
,23609389,terminal half-life,"The pharmacokinetic profile of almorexant was characterized by a median time to the maximum concentration of 1.5 hours, quick disposition with a distribution half-life of 1.6 hours, and rapidly decreasing concentrations to approximately 20% of the maximum concentration over 8 hours, with a terminal half-life of 32 hours.","Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23609389/),h,32,82084,DB00425,Zolpidem
,2612539,apparent elimination half life,"The apparent elimination half life, estimated from plasma zolpidem concentrations was 2.6 h.",Zolpidem excretion in breast milk. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612539/),h,2.6,89383,DB00425,Zolpidem
,2612539,apparent breast milk clearance,"The apparent breast milk clearance of zolpidem, calculated from the ratio of the total amount of zolpidem excreted in milk to its AUC in plasma was 1.48 ml/h.",Zolpidem excretion in breast milk. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612539/),[ml] / [h],1.48,89384,DB00425,Zolpidem
below,2612539,excretion,The results show that the excretion of zolpidem in human milk is very low (below 0.02%) and that most of it takes place during the first 3 h following drug intake.,Zolpidem excretion in breast milk. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612539/),%,0.,89385,DB00425,Zolpidem
,20376002,time to maximum concentration (t(max)),"Peak plasma concentration (C(max)) was quickly attained (median time to maximum concentration (t(max)) ranged from 0.7 to 2.3 h), and plasma concentrations subsequently decreased quickly to ~20% of C(max) over the course of 8 h.","Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20376002/),h,0.7 to 2.3,89769,DB00425,Zolpidem
,8634767,detection limits,"The detection limits are 1 and 2 ng/ml for zolpidem and zopiclone, respectively.",Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8634767/),[ng] / [ml],1,96810,DB00425,Zolpidem
,8634767,detection limits,"The detection limits are 1 and 2 ng/ml for zolpidem and zopiclone, respectively.",Simultaneous determination of zolpidem and zopiclone in human plasma by gas chromatography-nitrogen-phosphorus detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8634767/),[ng] / [ml],2,96811,DB00425,Zolpidem
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,251.20,97928,DB00425,Zolpidem
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,206.10,97929,DB00425,Zolpidem
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,86.20,97930,DB00425,Zolpidem
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,308.10,97931,DB00425,Zolpidem
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,235.10,97932,DB00425,Zolpidem
,17296337,overall recoveries,"The overall recoveries for rivastigmine and zolpidem were 86.28% and 87.57%, respectively.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),%,86.28,97933,DB00425,Zolpidem
,17296337,overall recoveries,"The overall recoveries for rivastigmine and zolpidem were 86.28% and 87.57%, respectively.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),%,87.57,97934,DB00425,Zolpidem
,17296337,total run time,The total run time was 2.0 min.,A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),min,2.0,97935,DB00425,Zolpidem
,28262178,terminal elimination half-life (t½),"Peak plasma concentration (Tmax) of zolpidem-IR occurs in 45 to 60min, with the terminal elimination half-life (t½) equating to 2.4h.",Zolpidem's use for insomnia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28262178/),h,2.4,98023,DB00425,Zolpidem
,27901207,peak plasma concentration,"In vivo studies revealed that administration of zolpidem nanosphere-impregnated film enhanced absorption of the drug (p < 0.0001), with a higher peak plasma concentration (52.54 ± 8.22 ng/mL) and area under the curve from time 0 to α (236.00 ± 39.51 ng.h/mL) than oral administration.",In vitro and in vivo evaluation of nano-based films for buccal delivery of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901207/),[ng] / [ml],52.54,103495,DB00425,Zolpidem
,27901207,area under the curve from time 0 to α,"In vivo studies revealed that administration of zolpidem nanosphere-impregnated film enhanced absorption of the drug (p < 0.0001), with a higher peak plasma concentration (52.54 ± 8.22 ng/mL) and area under the curve from time 0 to α (236.00 ± 39.51 ng.h/mL) than oral administration.",In vitro and in vivo evaluation of nano-based films for buccal delivery of zolpidem. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901207/),[h·ng] / [ml],236.00,103496,DB00425,Zolpidem
,27901207,time,The increase in time taken to reach the maximum drug concentration (1.5 h) further signifies the potential of these films to provide prolonged drug release.,In vitro and in vivo evaluation of nano-based films for buccal delivery of zolpidem. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27901207/),h,1.5,103497,DB00425,Zolpidem
,10935688,elimination half-life,"In the clinical study, ritonavir reduced triazolam clearance to < 4% of control values (p < .005), prolonged elimination half-life (41 versus 3 hours; p < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment.",Differential impairment of triazolam and zolpidem clearance by ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935688/),h,41,107581,DB00425,Zolpidem
,10935688,elimination half-life,"In the clinical study, ritonavir reduced triazolam clearance to < 4% of control values (p < .005), prolonged elimination half-life (41 versus 3 hours; p < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment.",Differential impairment of triazolam and zolpidem clearance by ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935688/),h,3,107582,DB00425,Zolpidem
,10935688,elimination half-life,"In contrast, ritonavir reduced zolpidem clearance to 78% of control values (p < .08), and slightly prolonged elimination half-life (2.4 versus 2.0 hours; NS).",Differential impairment of triazolam and zolpidem clearance by ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935688/),h,2.4,107583,DB00425,Zolpidem
,10935688,elimination half-life,"In contrast, ritonavir reduced zolpidem clearance to 78% of control values (p < .08), and slightly prolonged elimination half-life (2.4 versus 2.0 hours; NS).",Differential impairment of triazolam and zolpidem clearance by ritonavir. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935688/),h,2.0,107584,DB00425,Zolpidem
,23798332,total run time,The total run time was 2.5 min.,Development and validation of automated SPE-LC-MS/MS method for determination of indapamide in human whole blood and its application to real study samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23798332/),min,2.5,110365,DB00425,Zolpidem
,23798332,absolute recoveries,The absolute recoveries of indapamide were 90.51-93.90%.,Development and validation of automated SPE-LC-MS/MS method for determination of indapamide in human whole blood and its application to real study samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23798332/),%,90.51-93.90,110366,DB00425,Zolpidem
,25567214,peak plasma concentration (C max),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[μg] / [ml],4.61,115254,DB00425,Zolpidem
,25567214,peak plasma concentration (C max),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[μg] / [ml],4.72,115255,DB00425,Zolpidem
,25567214,time to Cmax (t max),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),h,4.63,115256,DB00425,Zolpidem
,25567214,time to Cmax (t max),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),h,3.64,115257,DB00425,Zolpidem
,25567214,area under plasma concentration-time curve extrapolated to infinity (AUC0-∞),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[h·μg] / [ml],53.4,115258,DB00425,Zolpidem
,25567214,area under plasma concentration-time curve extrapolated to infinity (AUC0-∞),"For gabapentin + zolpidem combination versus gabapentin alone, mean pharmacokinetic parameters were peak plasma concentration (C max) 4.61 versus 4.72 µg/mL, time to Cmax (t max) 4.63 versus 3.64 h and the area under plasma concentration-time curve extrapolated to infinity (AUC0-∞) 53.4 versus 51.0 µg h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[h·μg] / [ml],51.0,115259,DB00425,Zolpidem
,25567214,C max,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[ng] / [ml],154,115260,DB00425,Zolpidem
,25567214,C max,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[ng] / [ml],138,115261,DB00425,Zolpidem
,25567214,t max,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),h,1.45,115262,DB00425,Zolpidem
,25567214,t max,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),h,1.84,115263,DB00425,Zolpidem
,25567214,AUC0-∞,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[h·ng] / [ml],912,115264,DB00425,Zolpidem
,25567214,AUC0-∞,"For the combination versus zolpidem alone, mean pharmacokinetic parameters were C max 154 versus 138 ng/mL, t max 1.45 versus 1.84 h and AUC0-∞ 912 versus 854 ng h/mL.","Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567214/),[h·ng] / [ml],854,115265,DB00425,Zolpidem
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],759,120029,DB00425,Zolpidem
,9626922,total area under the plasma zolpidem concentration-time curve (AUC0-infinity),Itraconazole had no marked effects on the pharmacokinetics of zolpidem; the total area under the plasma zolpidem concentration-time curve (AUC0-infinity) was 34% larger during the itraconazole phase (759 ng x h x ml(-1)) than during the placebo phase (567 ng x h x ml(-1)).,Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626922/),[h·ng] / [ml],567,120030,DB00425,Zolpidem
,20012430,half maximal inactivation (K (I)),"In HLMs, the concentration required for half maximal inactivation (K (I)) was 122 microM and the maximal rate of inactivation (k (inact)) was 0.094 min(-1).",In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012430/),μM,122,120069,DB00425,Zolpidem
,20012430,maximal rate of inactivation (k (inact)),"In HLMs, the concentration required for half maximal inactivation (K (I)) was 122 microM and the maximal rate of inactivation (k (inact)) was 0.094 min(-1).",In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012430/),1/[min],0.094,120070,DB00425,Zolpidem
,20012430,K (I),"In comparison, K (I) and k (inact) values with rCYP3A4 were 50 microM and 0.229 min(-1), respectively.",In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012430/),μM,50,120071,DB00425,Zolpidem
,20012430,k (inact),"In comparison, K (I) and k (inact) values with rCYP3A4 were 50 microM and 0.229 min(-1), respectively.",In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012430/),1/[min],0.229,120072,DB00425,Zolpidem
,22767645,flow rate,"The eluted samples were chromatographed on a Grace Smart RP 18 4.6 × 100 mm, 3 µ column by using a 95:5 v/v mixture of methanol and ammonium acetate buffer (30 mM, pH 5.0 ± 0.05) as a gradient mobile phase at a flow rate of 0.6 mL/min, and analyzed by mass spectrometry in the multiple reaction monitoring mode using the [M + H](+) ions m/z 448.03 → 285.14 for aripiprazole and m/z 308.13 → 235.25 for the internal standard (zolpidem tartrate), respectively.",Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),[ml] / [min],0.6,123302,DB00425,Zolpidem
,22767645,Extraction recovery,Extraction recovery of aripiprazole from plasma was in the range 75.56-79.57%; mean recovery was 77.35%.,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),%,75.56-79.57,123303,DB00425,Zolpidem
,22767645,recovery,Extraction recovery of aripiprazole from plasma was in the range 75.56-79.57%; mean recovery was 77.35%.,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),%,77.35,123304,DB00425,Zolpidem
,22767645,T(max),The main pharmacokinetic parameters were T(max) = (4.00 ± 2.336) C(max) = (55.16 ± 13.490) and AUC = (1846.28 ± 484.686).,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),,4.00,123305,DB00425,Zolpidem
,22767645,C(max),The main pharmacokinetic parameters were T(max) = (4.00 ± 2.336) C(max) = (55.16 ± 13.490) and AUC = (1846.28 ± 484.686).,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),,55.16,123306,DB00425,Zolpidem
,22767645,AUC,The main pharmacokinetic parameters were T(max) = (4.00 ± 2.336) C(max) = (55.16 ± 13.490) and AUC = (1846.28 ± 484.686).,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),,1846.28,123307,DB00425,Zolpidem
,8521677,absolute bio-availability,Zolpidem is approximately 92% bound to plasma proteins; absolute bio-availability of zolpidem is about 70%.,Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),%,70,127592,DB00425,Zolpidem
,8521677,peak plasma concentration,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[μg] / [l],192 to 324,127593,DB00425,Zolpidem
,8521677,terminal elimination half-line,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),h,1.5 to 3.2,127594,DB00425,Zolpidem
,8521677,total clearance,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[ml] / [kg·min],0.24 to 0.27,127595,DB00425,Zolpidem
,11192136,apparent elimination half-life,The apparent elimination half-life of zaleplon (60.1+/-8.9 min) was significantly shorter than that of zolpidem (124.5+/-37.9 min) (P < 0.001).,"Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192136/),min,60.1,140696,DB00425,Zolpidem
,11192136,apparent elimination half-life,The apparent elimination half-life of zaleplon (60.1+/-8.9 min) was significantly shorter than that of zolpidem (124.5+/-37.9 min) (P < 0.001).,"Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192136/),min,124.5,140697,DB00425,Zolpidem
,11192136,se,The sedation scores of the zaleplon groups returned to baseline in less time than those of the zolpidem groups (4 vs 8 hours; P < 0.05).,"Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192136/),,4,140698,DB00425,Zolpidem
,11192136,se,The sedation scores of the zaleplon groups returned to baseline in less time than those of the zolpidem groups (4 vs 8 hours; P < 0.05).,"Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192136/),,8,140699,DB00425,Zolpidem
,21302033,peak plasma concentrations (Cmax),"In the two periods of treatments, the mean peak plasma concentrations (Cmax) were 75.73±28.34 ng/ml (zolpidem alone) and 80.58±22.40 ng/ml (zolpidem after pre-treatment with ciprofloxacin).",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),[ng] / [ml],75.73,143114,DB00425,Zolpidem
,21302033,peak plasma concentrations (Cmax),"In the two periods of treatments, the mean peak plasma concentrations (Cmax) were 75.73±28.34 ng/ml (zolpidem alone) and 80.58±22.40 ng/ml (zolpidem after pre-treatment with ciprofloxacin).",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),[ng] / [ml],80.58,143115,DB00425,Zolpidem
,21302033,tmax,"The tmax, times taken to reach Cmax, were 0.91±0.42 and 1.44±0.61 h, respectively, and the total areas under the curve (AUC0-∞) were 300.2±115.5 and 438.1±142.6 ng h/ml, respectively.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),h,0.91,143116,DB00425,Zolpidem
,21302033,tmax,"The tmax, times taken to reach Cmax, were 0.91±0.42 and 1.44±0.61 h, respectively, and the total areas under the curve (AUC0-∞) were 300.2±115.5 and 438.1±142.6 ng h/ml, respectively.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),h,1.44,143117,DB00425,Zolpidem
,21302033,total areas under the curve (AUC0-∞),"The tmax, times taken to reach Cmax, were 0.91±0.42 and 1.44±0.61 h, respectively, and the total areas under the curve (AUC0-∞) were 300.2±115.5 and 438.1±142.6 ng h/ml, respectively.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),[h·ng] / [ml],300.2,143118,DB00425,Zolpidem
,21302033,total areas under the curve (AUC0-∞),"The tmax, times taken to reach Cmax, were 0.91±0.42 and 1.44±0.61 h, respectively, and the total areas under the curve (AUC0-∞) were 300.2±115.5 and 438.1±142.6 ng h/ml, respectively.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),[h·ng] / [ml],438.1,143119,DB00425,Zolpidem
,21302033,half-life,The half-life of zolpidem was 2.39±0.53 h when administered alone and 3.34±0.87 h after pre-treatment with ciprofloxacin.,Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),h,2.39,143120,DB00425,Zolpidem
,21302033,half-life,The half-life of zolpidem was 2.39±0.53 h when administered alone and 3.34±0.87 h after pre-treatment with ciprofloxacin.,Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),h,3.34,143121,DB00425,Zolpidem
,21302033,bioavailability,"Ciprofloxacin interacts with zolpidem in healthy volunteers, raising its bioavailability by about 46%.",Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21302033/),%,46,143122,DB00425,Zolpidem
,12362929,apparent oral clearance,"Among all subjects, mean apparent oral clearance was 376 ml/min (5.8 ml/min/kg), elimination half-life was 2.4 hours, and maximum serum zolpidem concentration was 60 ng/ml.",Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362929/),[ml] / [min],376,151920,DB00425,Zolpidem
,12362929,elimination half-life,"Among all subjects, mean apparent oral clearance was 376 ml/min (5.8 ml/min/kg), elimination half-life was 2.4 hours, and maximum serum zolpidem concentration was 60 ng/ml.",Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362929/),h,2.4,151921,DB00425,Zolpidem
,12362929,maximum serum zolpidem concentration,"Among all subjects, mean apparent oral clearance was 376 ml/min (5.8 ml/min/kg), elimination half-life was 2.4 hours, and maximum serum zolpidem concentration was 60 ng/ml.",Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362929/),[ng] / [ml],60,151922,DB00425,Zolpidem
,12362929,Clearance,Clearance was higher (445 vs. 345 ml/min) and half-life was shorter (1.8 vs.,Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362929/),[ml] / [min],445,151923,DB00425,Zolpidem
,12362929,Clearance,Clearance was higher (445 vs. 345 ml/min) and half-life was shorter (1.8 vs.,Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362929/),[ml] / [min],345,151924,DB00425,Zolpidem
,12362929,half-life,Clearance was higher (445 vs. 345 ml/min) and half-life was shorter (1.8 vs.,Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12362929/),,1.8,151925,DB00425,Zolpidem
<,12608888,half-life,"According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8-24 hours) and long half-life (>24 hours).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,3,152307,DB00425,Zolpidem
,12608888,half-life,"According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8-24 hours) and long half-life (>24 hours).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,8-24,152308,DB00425,Zolpidem
>,12608888,half-life,"According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8-24 hours) and long half-life (>24 hours).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,24,152309,DB00425,Zolpidem
,12608888,half-life,Zaleplon is characterised by an ultrashort half-life (approximately 1 hour).,"New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,1,152310,DB00425,Zolpidem
,12608888,half-lives,"Zolpidem and zopiclone have longer half-lives (approximately 2.4 and 5 hours, respectively).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,2.4,152311,DB00425,Zolpidem
,12608888,half-lives,"Zolpidem and zopiclone have longer half-lives (approximately 2.4 and 5 hours, respectively).","New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12608888/),h,5,152312,DB00425,Zolpidem
,21098143,peak plasma concentrations (C(max)),"In the 2 periods of treatments, the mean peak plasma concentrations (C(max)) were 59 ng/mL (zolpidem alone) and 35 ng/mL (zolpidem after pretreatment with carbamazepine).",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),[ng] / [ml],59,152963,DB00425,Zolpidem
,21098143,peak plasma concentrations (C(max)),"In the 2 periods of treatments, the mean peak plasma concentrations (C(max)) were 59 ng/mL (zolpidem alone) and 35 ng/mL (zolpidem after pretreatment with carbamazepine).",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),[ng] / [ml],35,152964,DB00425,Zolpidem
,21098143,t(max),"The t(max), times taken to reach C(max), were 0.9 hours and 1.0 hour, respectively, and the total areas under the curve (AUC(0-∞)) were 234.9 ng·h/mL and 101.5 ng·h/mL, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),h,0.9,152965,DB00425,Zolpidem
,21098143,t(max),"The t(max), times taken to reach C(max), were 0.9 hours and 1.0 hour, respectively, and the total areas under the curve (AUC(0-∞)) were 234.9 ng·h/mL and 101.5 ng·h/mL, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),h,1.0,152966,DB00425,Zolpidem
,21098143,total areas under the curve (AUC(0-∞)),"The t(max), times taken to reach C(max), were 0.9 hours and 1.0 hour, respectively, and the total areas under the curve (AUC(0-∞)) were 234.9 ng·h/mL and 101.5 ng·h/mL, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),[h·ng] / [ml],234.9,152967,DB00425,Zolpidem
,21098143,total areas under the curve (AUC(0-∞)),"The t(max), times taken to reach C(max), were 0.9 hours and 1.0 hour, respectively, and the total areas under the curve (AUC(0-∞)) were 234.9 ng·h/mL and 101.5 ng·h/mL, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),[h·ng] / [ml],101.5,152968,DB00425,Zolpidem
,21098143,half-life,"The half-life of zolpidem was 2.3 and 1.6 hours, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),h,2.3,152969,DB00425,Zolpidem
,21098143,half-life,"The half-life of zolpidem was 2.3 and 1.6 hours, respectively.",Pharmacokinetic interaction between zolpidem and carbamazepine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21098143/),h,1.6,152970,DB00425,Zolpidem
,12472987,elimination half-life,"Plasma pharmacokinetic analysis demonstrated a prolonged elimination half-life of venlafaxine, estimated to be 15.3 h.",Alternative venlafaxine kinetics in overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472987/),h,15.3,162006,DB00425,Zolpidem
,27189774,Cmax,"In comparison with solution formulation (ZLP-S03), the optimized mucoadhesive formulation (ZLP-B01) containing 0.25% hydroxypropyl methylcellulose was found to improve Cmax from 352.6 ± 86.0 to 555.7 ± 175.8 ng/mL, and AUC0-inf from 32,890 ± 7547 to 65,447 ± 36,996 ng·min/mL with mild nasal ciliotoxicity in rats.","Zolpidem Mucoadhesive Formulations for Intranasal Delivery: Characterization, In Vitro Permeability, Pharmacokinetics, and Nasal Ciliotoxicity in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27189774/),[ng] / [ml],352.6,165766,DB00425,Zolpidem
,27189774,Cmax,"In comparison with solution formulation (ZLP-S03), the optimized mucoadhesive formulation (ZLP-B01) containing 0.25% hydroxypropyl methylcellulose was found to improve Cmax from 352.6 ± 86.0 to 555.7 ± 175.8 ng/mL, and AUC0-inf from 32,890 ± 7547 to 65,447 ± 36,996 ng·min/mL with mild nasal ciliotoxicity in rats.","Zolpidem Mucoadhesive Formulations for Intranasal Delivery: Characterization, In Vitro Permeability, Pharmacokinetics, and Nasal Ciliotoxicity in Rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27189774/),[ng] / [ml],555.7,165767,DB00425,Zolpidem
,27189774,AUC0-inf,"In comparison with solution formulation (ZLP-S03), the optimized mucoadhesive formulation (ZLP-B01) containing 0.25% hydroxypropyl methylcellulose was found to improve Cmax from 352.6 ± 86.0 to 555.7 ± 175.8 ng/mL, and AUC0-inf from 32,890 ± 7547 to 65,447 ± 36,996 ng·min/mL with mild nasal ciliotoxicity in rats.","Zolpidem Mucoadhesive Formulations for Intranasal Delivery: Characterization, In Vitro Permeability, Pharmacokinetics, and Nasal Ciliotoxicity in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27189774/),[min·ng] / [ml],"32,890",165768,DB00425,Zolpidem
,27189774,AUC0-inf,"In comparison with solution formulation (ZLP-S03), the optimized mucoadhesive formulation (ZLP-B01) containing 0.25% hydroxypropyl methylcellulose was found to improve Cmax from 352.6 ± 86.0 to 555.7 ± 175.8 ng/mL, and AUC0-inf from 32,890 ± 7547 to 65,447 ± 36,996 ng·min/mL with mild nasal ciliotoxicity in rats.","Zolpidem Mucoadhesive Formulations for Intranasal Delivery: Characterization, In Vitro Permeability, Pharmacokinetics, and Nasal Ciliotoxicity in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27189774/),[min·ng] / [ml],"65,447",165769,DB00425,Zolpidem
,12449497,constant plasma concentrations,Ethanol was administered as a constant rate infusion resulting in constant plasma concentrations of 0.5 g/l.,"Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[g] / [l],0.5,167442,DB00425,Zolpidem
,12449497,EC50,"The values of the EC50 were 76 +/- 11, 12 +/- 3, and 512 +/- 116 ng/ml for midazolam, bretazenil, and zolpidem respectively.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[ng] / [ml],76,167443,DB00425,Zolpidem
,12449497,EC50,"The values of the EC50 were 76 +/- 11, 12 +/- 3, and 512 +/- 116 ng/ml for midazolam, bretazenil, and zolpidem respectively.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[ng] / [ml],12,167444,DB00425,Zolpidem
,12449497,EC50,"The values of the EC50 were 76 +/- 11, 12 +/- 3, and 512 +/- 116 ng/ml for midazolam, bretazenil, and zolpidem respectively.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[ng] / [ml],512,167445,DB00425,Zolpidem
,12449497,Emax,"The values of the Emax were 113 +/- 9, 44 +/- 3, and 175 +/- 10 microV/s.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[μv] / [s],113,167446,DB00425,Zolpidem
,12449497,Emax,"The values of the Emax were 113 +/- 9, 44 +/- 3, and 175 +/- 10 microV/s.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[μv] / [s],44,167447,DB00425,Zolpidem
,12449497,Emax,"The values of the Emax were 113 +/- 9, 44 +/- 3, and 175 +/- 10 microV/s.","Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12449497/),[μv] / [s],175,167448,DB00425,Zolpidem
<,11981222,inter-response times (IRTs),Zolpidem increased the shorter-response [inter-response times (IRTs)<45 s] rate and decreased the reinforcement rate in a dose- and time-related fashion.,The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981222/),s,45,185938,DB00425,Zolpidem
,11981222,distributional,"Pharmacokinetically, zolpidem decays biexponentially with distributional and terminal elimination half-lives of 5.2 and 42 min, respectively.",The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981222/),min,5.2,185939,DB00425,Zolpidem
,11981222,terminal elimination half-lives,"Pharmacokinetically, zolpidem decays biexponentially with distributional and terminal elimination half-lives of 5.2 and 42 min, respectively.",The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981222/),min,42,185940,DB00425,Zolpidem
,11981222,absorption rate constant,"The absorption rate constant and absolute bioavailability for s.c. zolpidem were 0.083/min and of 84.1%, respectively.",The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981222/),1/[min],0.083,185941,DB00425,Zolpidem
,11981222,absolute bioavailability,"The absorption rate constant and absolute bioavailability for s.c. zolpidem were 0.083/min and of 84.1%, respectively.",The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981222/),%,84.1,185942,DB00425,Zolpidem
,11981222,pot,"The pharmacokinetic-pharmacodynamic analysis revealed that the potency of zolpidem (concentration required to produce 50% maximal effects, IC(50)) in disrupting the timing performance was 0.129 microg/ml.",The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11981222/),[μg] / [ml],0.129,185943,DB00425,Zolpidem
,10773013,Weight-normalized clearance,"Weight-normalized clearance of triazolam was higher in women than in men (8.7 versus 5. 5 ml/min/kg), but the difference was not significant.",Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773013/),[ml] / [kg·min],8.7,187193,DB00425,Zolpidem
,10773013,Weight-normalized clearance,"Weight-normalized clearance of triazolam was higher in women than in men (8.7 versus 5. 5 ml/min/kg), but the difference was not significant.",Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773013/),[ml] / [kg·min],5. 5,187194,DB00425,Zolpidem
,10773013,clearance,"In contrast, zolpidem clearance was lower in women than in men (3.5 versus 6.7 ml/min/kg, P <.06).",Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773013/),[ml] / [kg·min],3.5,187195,DB00425,Zolpidem
,10773013,clearance,"In contrast, zolpidem clearance was lower in women than in men (3.5 versus 6.7 ml/min/kg, P <.06).",Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10773013/),[ml] / [kg·min],6.7,187196,DB00425,Zolpidem
,9660843,t1/2,"There was a statistically significantly increased t1/2 for zolpidem on night 32, compared with night 28 (3.64 and 3.29 hr, respectively).",Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660843/),h,3.64,202340,DB00425,Zolpidem
,9660843,t1/2,"There was a statistically significantly increased t1/2 for zolpidem on night 32, compared with night 28 (3.64 and 3.29 hr, respectively).",Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660843/),h,3.29,202341,DB00425,Zolpidem
,30912258,half-lives,"Both zolpidem and ZPCA could be detected in oral fluid after 1 hour and were rapidly eliminated, with half-lives of 2.77 ± 0.71 hours and 5.11 ± 0.67 hours, respectively.",Zolpidem and zolpidem phenyl-4-carboxylic acid pharmacokinetics in oral fluid after a single dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30912258/),h,2.77,206341,DB00425,Zolpidem
,30912258,half-lives,"Both zolpidem and ZPCA could be detected in oral fluid after 1 hour and were rapidly eliminated, with half-lives of 2.77 ± 0.71 hours and 5.11 ± 0.67 hours, respectively.",Zolpidem and zolpidem phenyl-4-carboxylic acid pharmacokinetics in oral fluid after a single dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30912258/),h,5.11,206342,DB00425,Zolpidem
,30912258,Maximum zolpidem concentrations,"Maximum zolpidem concentrations (36.73 ± 10.89 ng/mL) occurred at 2 ± 0.52 hours, and maximum ZPCA concentrations (0.28 ± 0.16 ng/mL) occurred at 2 ± 0.37 hours.",Zolpidem and zolpidem phenyl-4-carboxylic acid pharmacokinetics in oral fluid after a single dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30912258/),[ng] / [ml],36.73,206343,DB00425,Zolpidem
,30912258,maximum ZPCA concentrations,"Maximum zolpidem concentrations (36.73 ± 10.89 ng/mL) occurred at 2 ± 0.52 hours, and maximum ZPCA concentrations (0.28 ± 0.16 ng/mL) occurred at 2 ± 0.37 hours.",Zolpidem and zolpidem phenyl-4-carboxylic acid pharmacokinetics in oral fluid after a single dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30912258/),[ng] / [ml],0.28,206344,DB00425,Zolpidem
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],336,212367,DB00425,Zolpidem
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],1202,212368,DB00425,Zolpidem
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],293,212369,DB00425,Zolpidem
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],117,212370,DB00425,Zolpidem
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,2.5,212371,DB00425,Zolpidem
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,1.6,212372,DB00425,Zolpidem
,23404347,half-life,Their pharmacokinetics approach those of the ideal hypnotic with rapid onset within 30 min and short half-life (1-7 h).,The clinical and forensic toxicology of Z-drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23404347/),h,1-7,214122,DB00425,Zolpidem
,16867025,half-value duration (HVD),This was confirmed by an increase in half-value duration (HVD) from 2.3 h with zolpidem-IR to 4.6 h with zolpidem-MR 12.5 mg.,Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867025/),h,2.3,214161,DB00425,Zolpidem
,16867025,half-value duration (HVD),This was confirmed by an increase in half-value duration (HVD) from 2.3 h with zolpidem-IR to 4.6 h with zolpidem-MR 12.5 mg.,Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867025/),h,4.6,214162,DB00425,Zolpidem
,12919178,apparent oral clearance,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ml] / [kg·min],3.8,222107,DB00425,Zolpidem
,12919178,apparent oral clearance,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ml] / [kg·min],11.0,222108,DB00425,Zolpidem
,12919178,Cmax,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ng] / [ml],93,222109,DB00425,Zolpidem
,12919178,Cmax,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ng] / [ml],40,222110,DB00425,Zolpidem
,12919178,half-life,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),h,2.7,222111,DB00425,Zolpidem
,12919178,half-life,"Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),h,1.5,222112,DB00425,Zolpidem
,12919178,oral clearance,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ml] / [kg·min],3.0,222113,DB00425,Zolpidem
,12919178,oral clearance,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ml] / [kg·min],5.8,222114,DB00425,Zolpidem
,12919178,Cmax,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ng] / [ml],108,222115,DB00425,Zolpidem
,12919178,Cmax,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),[ng] / [ml],60,222116,DB00425,Zolpidem
,12919178,t1/2,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),h,2.3,222117,DB00425,Zolpidem
,12919178,t1/2,"Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h).",Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919178/),h,2.4,222118,DB00425,Zolpidem
,23013193,minimal plasma concentration,"The desired clinical effects were not evident at plasma zolpidem concentrations ≤ 30 ng/mL, and the minimal plasma concentration that induced adverse effects was 60 ng/mL.",Pharmacokinetics and pharmacodynamics of zolpidem after oral administration of a single dose in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013193/),[ng] / [ml],60,222632,DB00425,Zolpidem
,27568900,Tmax,"Plasma zolpidem concentrations rapidly increased after intranasal ZNS 1.75, 3.5, and 5.0 mg with mean Tmax of 0.42, 0.76 and 0.50 h, respectively, followed by rapid decreases at all three doses.",Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27568900/),h,0.42,227936,DB00425,Zolpidem
,27568900,Tmax,"Plasma zolpidem concentrations rapidly increased after intranasal ZNS 1.75, 3.5, and 5.0 mg with mean Tmax of 0.42, 0.76 and 0.50 h, respectively, followed by rapid decreases at all three doses.",Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27568900/),h,0.76,227937,DB00425,Zolpidem
,27568900,Tmax,"Plasma zolpidem concentrations rapidly increased after intranasal ZNS 1.75, 3.5, and 5.0 mg with mean Tmax of 0.42, 0.76 and 0.50 h, respectively, followed by rapid decreases at all three doses.",Pharmacokinetics of a Novel Zolpidem Nasal Spray for Rapid Management of Insomnia: First Trial in Humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27568900/),h,0.50,227938,DB00425,Zolpidem
,23939537,Area under the concentration-time curve (AUC),Area under the concentration-time curve (AUC) values for the 0-8 h interval were 160 ng/mL h in the fed state and 203 ng/mL h in the fasting state (P < .001).,Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23939537/),[ng] / [h·ml],160,230358,DB00425,Zolpidem
,23939537,Area under the concentration-time curve (AUC),Area under the concentration-time curve (AUC) values for the 0-8 h interval were 160 ng/mL h in the fed state and 203 ng/mL h in the fasting state (P < .001).,Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23939537/),[ng] / [h·ml],203,230359,DB00425,Zolpidem
,23939537,Cmax,"In the fed versus fasting states, Cmax was 32.0 ng/mL versus 57.3 ng/mL (P < .001), respectively, and Tmax was 3.0 h versus 0.92 h (P < .001), respectively.",Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23939537/),[ng] / [ml],32.0,230360,DB00425,Zolpidem
,23939537,Cmax,"In the fed versus fasting states, Cmax was 32.0 ng/mL versus 57.3 ng/mL (P < .001), respectively, and Tmax was 3.0 h versus 0.92 h (P < .001), respectively.",Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23939537/),[ng] / [ml],57.3,230361,DB00425,Zolpidem
,23939537,Tmax,"In the fed versus fasting states, Cmax was 32.0 ng/mL versus 57.3 ng/mL (P < .001), respectively, and Tmax was 3.0 h versus 0.92 h (P < .001), respectively.",Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23939537/),h,3.0,230362,DB00425,Zolpidem
,23939537,Tmax,"In the fed versus fasting states, Cmax was 32.0 ng/mL versus 57.3 ng/mL (P < .001), respectively, and Tmax was 3.0 h versus 0.92 h (P < .001), respectively.",Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23939537/),h,0.92,230363,DB00425,Zolpidem
,17101746,Time of peak plasma concentration (tmax),"Time of peak plasma concentration (tmax) was significantly longer for MR (2.4 vs 2.0 hours, P < .004), and dose-normalized peak plasma concentration (Cmax) was lower (12.2 vs 14.0 ng/mL/mg, P < .001).",Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101746/),h,2.4,231198,DB00425,Zolpidem
,17101746,Time of peak plasma concentration (tmax),"Time of peak plasma concentration (tmax) was significantly longer for MR (2.4 vs 2.0 hours, P < .004), and dose-normalized peak plasma concentration (Cmax) was lower (12.2 vs 14.0 ng/mL/mg, P < .001).",Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101746/),h,2.0,231199,DB00425,Zolpidem
,17101746,dose-normalized peak plasma concentration (Cmax),"Time of peak plasma concentration (tmax) was significantly longer for MR (2.4 vs 2.0 hours, P < .004), and dose-normalized peak plasma concentration (Cmax) was lower (12.2 vs 14.0 ng/mL/mg, P < .001).",Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101746/),[ng] / [mg·ml],12.2,231200,DB00425,Zolpidem
,17101746,dose-normalized peak plasma concentration (Cmax),"Time of peak plasma concentration (tmax) was significantly longer for MR (2.4 vs 2.0 hours, P < .004), and dose-normalized peak plasma concentration (Cmax) was lower (12.2 vs 14.0 ng/mL/mg, P < .001).",Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101746/),[ng] / [mg·ml],14.0,231201,DB00425,Zolpidem
,15005637,bioavailability,"Although zaleplon has a much lower bioavailability (30%), the treatment dose is similar to zolpidem and zopiclone (bioavilaibility of 70%) because of the increased potency of zaleplon.","Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005637/),%,30,236145,DB00425,Zolpidem
,15005637,bioavilaibility,"Although zaleplon has a much lower bioavailability (30%), the treatment dose is similar to zolpidem and zopiclone (bioavilaibility of 70%) because of the increased potency of zaleplon.","Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005637/),%,70,236146,DB00425,Zolpidem
,23541711,plasma concentrations at,"After 3.5-mg ZST and 10-mg IR, respectively, mean zolpidem plasma concentrations at 15 minutes (22 vs 17 ng/mL, respectively, in females and 18 vs 10 ng/mL in males) and AUCs from zero to 15 minutes (2.3 vs 0.8 ng · h/mL in females and 1.6 vs 0.5 ng · h/mL in males) were substantially greater for ZST, despite the larger absolute IR dose.","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[ng] / [ml],22,241200,DB00425,Zolpidem
,23541711,plasma concentrations at,"After 3.5-mg ZST and 10-mg IR, respectively, mean zolpidem plasma concentrations at 15 minutes (22 vs 17 ng/mL, respectively, in females and 18 vs 10 ng/mL in males) and AUCs from zero to 15 minutes (2.3 vs 0.8 ng · h/mL in females and 1.6 vs 0.5 ng · h/mL in males) were substantially greater for ZST, despite the larger absolute IR dose.","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[ng] / [ml],17,241201,DB00425,Zolpidem
,23541711,plasma concentrations at,"After 3.5-mg ZST and 10-mg IR, respectively, mean zolpidem plasma concentrations at 15 minutes (22 vs 17 ng/mL, respectively, in females and 18 vs 10 ng/mL in males) and AUCs from zero to 15 minutes (2.3 vs 0.8 ng · h/mL in females and 1.6 vs 0.5 ng · h/mL in males) were substantially greater for ZST, despite the larger absolute IR dose.","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[ng] / [ml],18,241202,DB00425,Zolpidem
,23541711,plasma concentrations at,"After 3.5-mg ZST and 10-mg IR, respectively, mean zolpidem plasma concentrations at 15 minutes (22 vs 17 ng/mL, respectively, in females and 18 vs 10 ng/mL in males) and AUCs from zero to 15 minutes (2.3 vs 0.8 ng · h/mL in females and 1.6 vs 0.5 ng · h/mL in males) were substantially greater for ZST, despite the larger absolute IR dose.","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[ng] / [ml],10,241203,DB00425,Zolpidem
,23541711,AUCs from zero to 15 minutes,"After 3.5-mg ZST and 10-mg IR, respectively, mean zolpidem plasma concentrations at 15 minutes (22 vs 17 ng/mL, respectively, in females and 18 vs 10 ng/mL in males) and AUCs from zero to 15 minutes (2.3 vs 0.8 ng · h/mL in females and 1.6 vs 0.5 ng · h/mL in males) were substantially greater for ZST, despite the larger absolute IR dose.","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[h·ng] / [ml],2.3,241204,DB00425,Zolpidem
,23541711,AUCs from zero to 15 minutes,"After 3.5-mg ZST and 10-mg IR, respectively, mean zolpidem plasma concentrations at 15 minutes (22 vs 17 ng/mL, respectively, in females and 18 vs 10 ng/mL in males) and AUCs from zero to 15 minutes (2.3 vs 0.8 ng · h/mL in females and 1.6 vs 0.5 ng · h/mL in males) were substantially greater for ZST, despite the larger absolute IR dose.","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[h·ng] / [ml],0.8,241205,DB00425,Zolpidem
,23541711,AUCs from zero to 15 minutes,"After 3.5-mg ZST and 10-mg IR, respectively, mean zolpidem plasma concentrations at 15 minutes (22 vs 17 ng/mL, respectively, in females and 18 vs 10 ng/mL in males) and AUCs from zero to 15 minutes (2.3 vs 0.8 ng · h/mL in females and 1.6 vs 0.5 ng · h/mL in males) were substantially greater for ZST, despite the larger absolute IR dose.","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[h·ng] / [ml],1.6,241206,DB00425,Zolpidem
,23541711,AUCs from zero to 15 minutes,"After 3.5-mg ZST and 10-mg IR, respectively, mean zolpidem plasma concentrations at 15 minutes (22 vs 17 ng/mL, respectively, in females and 18 vs 10 ng/mL in males) and AUCs from zero to 15 minutes (2.3 vs 0.8 ng · h/mL in females and 1.6 vs 0.5 ng · h/mL in males) were substantially greater for ZST, despite the larger absolute IR dose.","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[h·ng] / [ml],0.5,241207,DB00425,Zolpidem
,23541711,clearance,"After 3.5-mg ZST and 10-mg IR, respectively, clearance was lower in females, even after correcting for body weight (2.63 vs 2.88 mL/min/kg in females and 3.63 vs 3.91 mL/min/kg in males).","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[ml] / [kg·min],2.63,241208,DB00425,Zolpidem
,23541711,clearance,"After 3.5-mg ZST and 10-mg IR, respectively, clearance was lower in females, even after correcting for body weight (2.63 vs 2.88 mL/min/kg in females and 3.63 vs 3.91 mL/min/kg in males).","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[ml] / [kg·min],2.88,241209,DB00425,Zolpidem
,23541711,clearance,"After 3.5-mg ZST and 10-mg IR, respectively, clearance was lower in females, even after correcting for body weight (2.63 vs 2.88 mL/min/kg in females and 3.63 vs 3.91 mL/min/kg in males).","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[ml] / [kg·min],3.63,241210,DB00425,Zolpidem
,23541711,clearance,"After 3.5-mg ZST and 10-mg IR, respectively, clearance was lower in females, even after correcting for body weight (2.63 vs 2.88 mL/min/kg in females and 3.63 vs 3.91 mL/min/kg in males).","Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),[ml] / [kg·min],3.91,241211,DB00425,Zolpidem
,23541711,lag time,The lag time prior to the start of first-order absorption was notably shorter for ZST than IR in both males (8 vs 21 minutes) and females (5 vs 22 minutes).,"Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),min,8,241212,DB00425,Zolpidem
,23541711,lag time,The lag time prior to the start of first-order absorption was notably shorter for ZST than IR in both males (8 vs 21 minutes) and females (5 vs 22 minutes).,"Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),min,21,241213,DB00425,Zolpidem
,23541711,lag time,The lag time prior to the start of first-order absorption was notably shorter for ZST than IR in both males (8 vs 21 minutes) and females (5 vs 22 minutes).,"Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),min,5,241214,DB00425,Zolpidem
,23541711,lag time,The lag time prior to the start of first-order absorption was notably shorter for ZST than IR in both males (8 vs 21 minutes) and females (5 vs 22 minutes).,"Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23541711/),min,22,241215,DB00425,Zolpidem
,16822278,half-life,"The time to peak plasma zolpidem concentration was unchanged by voriconazole but the half-life was prolonged from 3.2 to 4.1 h (P < 0.01; 95% CI on the difference 0.27, 1.45).",Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16822278/),h,3.2,244429,DB00425,Zolpidem
,16822278,half-life,"The time to peak plasma zolpidem concentration was unchanged by voriconazole but the half-life was prolonged from 3.2 to 4.1 h (P < 0.01; 95% CI on the difference 0.27, 1.45).",Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16822278/),h,4.1,244430,DB00425,Zolpidem
,23126273,half-life,"The mean half-life in healthy nonelderly individuals (6.1 h) is prolonged in the elderly, in patients with hepatic insufficiency, and by coadministration of CYP3A inhibitors.",Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23126273/),h,6.1,244675,DB00425,Zolpidem
,19094161,t(max),"Mean gaboxadol t(max) was 2 h, t((1/2)) was 1.7 h, AUC(0-infinity) was 430 ng.h ml(-1) and C(max) was 139 ng ml(-1).","Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19094161/),h,2,246369,DB00425,Zolpidem
,19094161,t((1/2)),"Mean gaboxadol t(max) was 2 h, t((1/2)) was 1.7 h, AUC(0-infinity) was 430 ng.h ml(-1) and C(max) was 139 ng ml(-1).","Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19094161/),h,1.7,246370,DB00425,Zolpidem
,19094161,AUC(0-infinity),"Mean gaboxadol t(max) was 2 h, t((1/2)) was 1.7 h, AUC(0-infinity) was 430 ng.h ml(-1) and C(max) was 139 ng ml(-1).","Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19094161/),[h·ng] / [ml],430,246371,DB00425,Zolpidem
,19094161,C(max),"Mean gaboxadol t(max) was 2 h, t((1/2)) was 1.7 h, AUC(0-infinity) was 430 ng.h ml(-1) and C(max) was 139 ng ml(-1).","Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19094161/),[ng] / [ml],139,246372,DB00425,Zolpidem
,24365985,Cmax,Seventy-three zolpidem concentrations were measured with a mean Cmax of 291 ± 140 ng/mL.,Preliminary assessment of zolpidem pharmacokinetics in pediatric burn patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365985/),[ng] / [ml],291,251893,DB00425,Zolpidem
,24365985,clearance,"Zolpidem clearance was estimated at 0.03 L·h(-1)·kg(-1) (relative standard error, 55%) and increased with body weight (P < 0.05).",Preliminary assessment of zolpidem pharmacokinetics in pediatric burn patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365985/),[l] / [h·kg],0.03,251894,DB00425,Zolpidem
,24365985,central compartment volume of distribution,"The central compartment volume of distribution was estimated at 0.05 L/kg (relative standard error, 25%), which was inversely related to the proportion of the body surface with third-degree burns (P < 0.001).",Preliminary assessment of zolpidem pharmacokinetics in pediatric burn patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365985/),[l] / [kg],0.05,251895,DB00425,Zolpidem
,19648220,T(max),"Zolpidem was absorbed and eliminated quickly, with a median T(max) of 0.78 h (range: 0.33-2.50) and t(1/2) of 2.2 h.","Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19648220/),h,0.78,256649,DB00425,Zolpidem
,19648220,t(1/2),"Zolpidem was absorbed and eliminated quickly, with a median T(max) of 0.78 h (range: 0.33-2.50) and t(1/2) of 2.2 h.","Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19648220/),h,2.2,256650,DB00425,Zolpidem
,7996394,concentrations,"The highest concentrations in plasma, which were observed at the first sampling time (0.5 h) were 2341 +/- 540 (day 0), 1956 +/- 325 (day 7) and 2908 +/- 1369 ng mL-1 (day 28).",Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),[ng] / [ml],2341,263129,DB00425,Zolpidem
,7996394,concentrations,"The highest concentrations in plasma, which were observed at the first sampling time (0.5 h) were 2341 +/- 540 (day 0), 1956 +/- 325 (day 7) and 2908 +/- 1369 ng mL-1 (day 28).",Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),[ng] / [ml],1956,263130,DB00425,Zolpidem
,7996394,concentrations,"The highest concentrations in plasma, which were observed at the first sampling time (0.5 h) were 2341 +/- 540 (day 0), 1956 +/- 325 (day 7) and 2908 +/- 1369 ng mL-1 (day 28).",Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),[ng] / [ml],2908,263131,DB00425,Zolpidem
,7996394,AUC,"Corresponding AUC values of 1742 +/- 488, 1583 +/- 422 and 2683 +/- 1249 ng mL-1 h were found.",Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),[h·ng] / [ml],1742,263132,DB00425,Zolpidem
,7996394,AUC,"Corresponding AUC values of 1742 +/- 488, 1583 +/- 422 and 2683 +/- 1249 ng mL-1 h were found.",Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),[h·ng] / [ml],1583,263133,DB00425,Zolpidem
,7996394,AUC,"Corresponding AUC values of 1742 +/- 488, 1583 +/- 422 and 2683 +/- 1249 ng mL-1 h were found.",Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),[h·ng] / [ml],2683,263134,DB00425,Zolpidem
,7996394,MRT,MRT increased significantly from 0.46 +/- 0.06 h on day 0 to 0.67 +/- 0.02 h on day 28.,Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),h,0.46,263135,DB00425,Zolpidem
,7996394,MRT,MRT increased significantly from 0.46 +/- 0.06 h on day 0 to 0.67 +/- 0.02 h on day 28.,Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),h,0.67,263136,DB00425,Zolpidem
,7996394,cerebral levels,"The cerebral levels showed no significant change during the chronic administration (766 +/- 285, 685 +/- 171 and 887 +/- 264 ng g-1, respectively).",Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),[ng] / [g],766,263137,DB00425,Zolpidem
,7996394,cerebral levels,"The cerebral levels showed no significant change during the chronic administration (766 +/- 285, 685 +/- 171 and 887 +/- 264 ng g-1, respectively).",Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),[ng] / [g],685,263138,DB00425,Zolpidem
,7996394,cerebral levels,"The cerebral levels showed no significant change during the chronic administration (766 +/- 285, 685 +/- 171 and 887 +/- 264 ng g-1, respectively).",Pharmacokinetics and brain distribution of zolpidem in the rat after acute and chronic administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7996394/),[ng] / [g],887,263139,DB00425,Zolpidem
